Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer’s Disease
暂无分享,去创建一个
Lisa Delano-Wood | Katherine J. Bangen | David P. Salmon | Mark W. Bondi | Ansgar J. Furst | D. Salmon | M. Bondi | A. Furst | K. Bangen | L. Delano-Wood | E. Edmonds | D. Nation | Daniel A. Nation | Emily C. Edmonds
[1] D. Salmon,et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. , 2014, Journal of Alzheimer's disease : JAD.
[2] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[3] Cindee M. Madison,et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.
[4] Keith A. Johnson,et al. The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials , 2014, Neuron.
[5] David T. Jones,et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity , 2013, Neurology.
[6] C. Jack,et al. An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.
[7] M. Bondi,et al. Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype. , 2016, Journal of Alzheimer's disease : JAD.
[8] Bradley T. Hyman,et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.
[9] D. Delis,et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[10] D. Y. Lee,et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.
[11] H. Braak,et al. Alzheimer's Disease: Striatal Amyloid Deposits and Neurofibrillary Changes , 1990, Journal of neuropathology and experimental neurology.
[12] Majaz Moonis,et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.
[13] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[14] J. Gunter,et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.
[15] Christos Davatzikos,et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings , 2013, Acta Neuropathologica Communications.
[16] Pedro Rosa-Neto,et al. Use of amyloid PET across the spectrum of Alzheimer’s disease: clinical utility and associated ethical issues , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[17] C. Jack,et al. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. , 2015, JAMA neurology.
[18] Tilo Kircher,et al. Accuracy and Reliability of Automated Gray Matter Segmentation Pathways on Real and Simulated Structural Magnetic Resonance Images of the Human Brain , 2012, PloS one.
[19] M. Weiner,et al. Relationships between biomarkers in aging and dementia , 2009, Neurology.
[20] R. Coleman,et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.
[21] M. Mintun,et al. Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.
[22] Sakari Savolainen,et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. , 2008, Archives of neurology.
[23] D. Salmon,et al. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.
[24] Charles D. Smith,et al. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.
[25] Douglas G Altman,et al. Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.
[26] D. Salmon,et al. "Missed" Mild Cognitive Impairment: High False-Negative Error Rate Based on Conventional Diagnostic Criteria. , 2016, Journal of Alzheimer's disease : JAD.
[27] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[28] Meghan B. Mitchell,et al. A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery , 2011, Alzheimer's Research & Therapy.
[29] Cindee M. Madison,et al. Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.
[30] Panteleimon Giannakopoulos,et al. Cerebral cortex pathology in aging and Alzheimer's disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts , 1997, Brain Research Reviews.
[31] H. Braak,et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.
[32] Sang Won Seo,et al. Amyloid deposition in early onset versus late onset Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.
[33] Jerry L. Prince,et al. A computational neurodegenerative disease progression score: Method and results with the Alzheimer's disease neuroimaging initiative cohort , 2012, NeuroImage.
[34] K. Ishii,et al. Amyloid β accumulation assessed with ¹¹C-Pittsburgh compound B PET and postmortem neuropathology. , 2015, Current Alzheimer research.
[35] Christos Davatzikos,et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition , 2014, Acta neuropathologica communications.
[36] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[37] M. Mintun,et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.
[38] Nathaniel Mercaldo,et al. The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychologic Test Battery , 2009, Alzheimer disease and associated disorders.
[39] L. Wilkins. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2017, Neurology.
[40] R. Petersen. Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.
[41] R. Elble,et al. The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease. , 1997, Neuropathology and applied neurobiology.
[42] J. Schneider,et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions , 2005, Neurology.
[43] M. Bondi,et al. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors , 2015, Alzheimer's & Dementia.
[44] Francis Eustache,et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease , 2013, NeuroImage: Clinical.
[45] Denise C. Park,et al. &bgr;-Amyloid burden in healthy aging: Regional distribution and cognitive consequences , 2012, Neurology.
[46] H. Braak,et al. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. , 2015, Brain : a journal of neurology.
[47] K. Blennow,et al. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid , 2013, Acta Neuropathologica.
[48] M. Mintun,et al. Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.
[49] D. Salmon,et al. Are Empirically-Derived Subtypes of Mild Cognitive Impairment Consistent with Conventional Subtypes? , 2013, Journal of the International Neuropsychological Society.
[50] M. Bondi,et al. Heterogeneous cortical atrophy patterns in MCI not captured by conventional diagnostic criteria , 2016, Neurology.
[51] C. Buckley,et al. Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology. , 2016, Journal of Alzheimer's disease : JAD.
[52] R. Brookmeyer,et al. Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementia , 2012, Neurology.
[53] F. Schmitt,et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. , 1999, Journal of neuropathology and experimental neurology.
[54] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[55] Rodger J. Elble,et al. The distribution of amyloid β protein deposition in the corpus striatum of patients with Alzheimer's disease , 1997 .
[56] James F. Malec,et al. Mayo's older americans normative studies: Updated AVLT norms for ages 56 to 97 , 1992 .
[57] A. Hirano,et al. Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease , 2004, Acta Neuropathologica.
[58] Owen Carmichael,et al. Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage. , 2013, Psychology and aging.
[59] J. Price,et al. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.